Laboratorio Farmaceutico Erfo S.p.A.

BIT:ERFO Stock Report

Market Cap: €10.2m

Laboratorio Farmaceutico Erfo Past Earnings Performance

Past criteria checks 1/6

Laboratorio Farmaceutico Erfo's earnings have been declining at an average annual rate of -24.8%, while the Personal Products industry saw earnings growing at 2.9% annually. Revenues have been growing at an average rate of 9.1% per year. Laboratorio Farmaceutico Erfo's return on equity is 5.4%, and it has net margins of 7.6%.

Key information

-24.8%

Earnings growth rate

-31.3%

EPS growth rate

Personal Products Industry Growth13.6%
Revenue growth rate9.1%
Return on equity5.4%
Net Margin7.6%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Is Now An Opportune Moment To Examine Laboratorio Farmaceutico Erfo S.p.A. (BIT:ERFO)?

Aug 17
Is Now An Opportune Moment To Examine Laboratorio Farmaceutico Erfo S.p.A. (BIT:ERFO)?

Revenue & Expenses Breakdown

How Laboratorio Farmaceutico Erfo makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BIT:ERFO Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 246010
31 Mar 246110
31 Dec 236110
30 Sep 236110
30 Jun 235110
31 Mar 235110
31 Dec 225110
30 Sep 225110
30 Jun 225110
31 Mar 225110
31 Dec 215110
31 Dec 204110
31 Dec 195110
31 Dec 184110

Quality Earnings: ERFO has high quality earnings.

Growing Profit Margin: ERFO's current net profit margins (7.6%) are lower than last year (12.7%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ERFO's earnings have declined by 24.8% per year over the past 5 years.

Accelerating Growth: ERFO's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: ERFO had negative earnings growth (-34.9%) over the past year, making it difficult to compare to the Personal Products industry average (10.8%).


Return on Equity

High ROE: ERFO's Return on Equity (5.4%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 03:33
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Laboratorio Farmaceutico Erfo S.p.A. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Federica FiorenzaKT & Partners Srl
Fusun BektasKT & Partners Srl
Maria Di GradoKT & Partners Srl